Inhibitor Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Inhibitor Therapeutics' 2024 annual report highlights ongoing efforts to develop itraconazole-based therapies for various cancers, with a focus on regulatory pathways and strategic partnerships.
OQB
Inhibitor Therapeutics, a pharmaceutical development company, released its 2023 annual report, highlighting progress in its cancer therapy development and a new licensing agreement with Johns Hopkins University.